PACIRA BIOSCIENCES, INC. Depreciation
PACIRA BIOSCIENCES, INC. (PCRX) reported Depreciation of $7.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. depreciation for the quarter ending 2026-06-30 was $7.00M, a 46.15% decline year-over-year.
- PACIRA BIOSCIENCES, INC. depreciation for the quarter ending 2026-03-31 was $7.00M, a 2.94% increase year-over-year.
- PACIRA BIOSCIENCES, INC. depreciation for the quarter ending 2025-12-31 was $7.00M, a 1.45% increase year-over-year.
- PACIRA BIOSCIENCES, INC. depreciation for the quarter ending 2025-09-30 was $6.90M, a 15.00% increase year-over-year.
- PACIRA BIOSCIENCES, INC. depreciation for fiscal 2025 was $33.70M, a 56.74% increase from fiscal 2024.
- PACIRA BIOSCIENCES, INC. depreciation for fiscal 2024 was $21.50M, a 17.49% increase from fiscal 2023.
- PACIRA BIOSCIENCES, INC. depreciation for fiscal 2023 was $18.30M, a 46.49% decline from fiscal 2022.
- PACIRA BIOSCIENCES, INC. depreciation for fiscal 2022 was $34.20M, a 128.00% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 3 month as first filed | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $7.00M 10-Q · filed 2026-08-04 | $14.00M 10-Q · filed 2026-08-04 | $21.00M derived: sum of 3 quarters · filed 2026-08-04 | $27.90M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2026-03-31 | $7.00M 10-Q · filed 2026-04-30 | $14.00M derived: sum of 2 quarters · filed 2026-04-30 | $20.90M derived: sum of 3 quarters · filed 2026-04-30 | $33.90M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-12-31 | $7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $13.90M derived: sum of 2 quarters · filed 2026-02-26 | $26.90M derived: sum of 3 quarters · filed 2026-08-04 | $33.70M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $6.90M 10-Q · filed 2025-11-06 | $19.90M derived: sum of 2 quarters · filed 2026-08-04 | $26.70M 10-Q · filed 2025-11-06 | $33.60M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-06-30 | $13.00M 10-Q · filed 2026-08-04 | $19.80M 10-Q · filed 2026-08-04 | $26.70M derived: sum of 3 quarters · filed 2026-08-04 | $32.70M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-03-31 | $6.80M 10-Q · filed 2026-04-30 | $13.70M derived: sum of 2 quarters · filed 2026-04-30 | $19.70M derived: sum of 3 quarters · filed 2026-04-30 | $24.20M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | $6.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $12.90M derived: sum of 2 quarters · filed 2026-02-26 | $17.40M derived: sum of 3 quarters · filed 2026-02-26 | $21.50M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $6.00M 10-Q · filed 2025-11-06 | $10.50M derived: sum of 2 quarters · filed 2025-11-06 | $14.60M 10-Q · filed 2025-11-06 | $18.80M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $4.50M 10-Q · filed 2025-08-05 | $8.60M 10-Q · filed 2025-08-05 | $12.80M derived: sum of 3 quarters · filed 2026-02-26 | $16.90M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $4.10M 10-Q · filed 2025-05-08 | $8.30M derived: sum of 2 quarters · filed 2026-02-26 | $12.40M derived: sum of 3 quarters · filed 2026-02-26 | $17.10M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $4.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.30M derived: sum of 2 quarters · filed 2026-02-26 | $13.00M derived: sum of 3 quarters · filed 2026-02-26 | $18.30M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $4.10M 10-Q · filed 2024-11-06 | $8.80M derived: sum of 2 quarters · filed 2024-11-06 | $14.10M 10-Q · filed 2024-11-06 | $30.30M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $4.70M 10-Q · filed 2024-07-30 | $10.00M 10-Q · filed 2024-07-30 | $26.20M derived: sum of 3 quarters · filed 2025-02-27 | $32.00M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $5.30M 10-Q · filed 2024-05-07 | $21.50M derived: sum of 2 quarters · filed 2025-02-27 | $27.30M derived: sum of 3 quarters · filed 2025-02-27 | $33.80M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $16.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $22.00M derived: sum of 2 quarters · filed 2025-02-27 | $28.50M derived: sum of 3 quarters · filed 2025-02-27 | $34.20M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $5.80M 10-Q · filed 2023-11-02 | $12.30M derived: sum of 2 quarters · filed 2023-11-02 | $18.00M 10-Q · filed 2023-11-02 | $23.40M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-06-30 | $6.50M 10-Q · filed 2023-08-02 | $12.20M 10-Q · filed 2023-08-02 | $17.60M derived: sum of 3 quarters · filed 2024-02-29 | $21.40M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-03-31 | $5.70M 10-Q · filed 2023-05-03 | $11.10M derived: sum of 2 quarters · filed 2024-02-29 | $14.90M derived: sum of 3 quarters · filed 2024-02-29 | $17.80M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2021-12-31 | $5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $9.20M derived: sum of 2 quarters · filed 2024-02-29 | $12.10M derived: sum of 3 quarters · filed 2024-02-29 | $15.00M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $3.80M 10-Q · filed 2022-11-03 | $6.70M derived: sum of 2 quarters · filed 2022-11-03 | $9.60M 10-Q · filed 2022-11-03 | $12.70M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-06-30 | $2.90M 10-Q · filed 2022-08-03 | $5.80M 10-Q · filed 2022-08-03 | $8.90M derived: sum of 3 quarters · filed 2023-02-28 | $12.00M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-03-31 | $2.90M 10-Q · filed 2022-05-04 | $6.00M derived: sum of 2 quarters · filed 2023-02-28 | $9.10M derived: sum of 3 quarters · filed 2023-02-28 | $12.10M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2020-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $6.20M derived: sum of 2 quarters · filed 2023-02-28 | $9.20M derived: sum of 3 quarters · filed 2023-02-28 | $12.00M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $3.10M 10-Q · filed 2021-11-03 | $6.10M derived: sum of 2 quarters · filed 2021-11-03 | $8.90M 10-Q · filed 2021-11-03 | $12.30M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-06-30 | $3.00M 10-Q · filed 2021-08-03 | $5.90M 10-Q · filed 2021-08-03 | $9.20M derived: sum of 3 quarters · filed 2022-02-28 | $12.80M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-03-31 | $2.90M 10-Q · filed 2021-05-04 | $6.20M derived: sum of 2 quarters · filed 2022-02-28 | $9.80M derived: sum of 3 quarters · filed 2022-02-28 | $13.30M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2019-12-31 | $3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $6.90M derived: sum of 2 quarters · filed 2022-02-28 | $10.40M derived: sum of 3 quarters · filed 2022-02-28 | $14.00M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $3.60M 10-Q · filed 2020-10-30 | $7.10M derived: sum of 2 quarters · filed 2020-10-30 | $10.70M 10-Q · filed 2020-10-30 | $14.80M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2019-06-30 | $3.50M 10-Q · filed 2020-08-06 | $7.10M 10-Q · filed 2020-08-06 | $11.20M derived: sum of 3 quarters · filed 2021-03-01 | $14.70M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2019-03-31 | $3.60M 10-Q · filed 2020-05-07 | $7.70M derived: sum of 2 quarters · filed 2021-03-01 | $11.20M derived: sum of 3 quarters · filed 2021-03-01 | $14.00M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2018-12-31 | $4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $7.60M derived: sum of 2 quarters · filed 2021-03-01 | $10.40M derived: sum of 3 quarters · filed 2021-03-01 | $13.20M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $3.50M 10-Q · filed 2019-11-08 | $6.30M derived: sum of 2 quarters · filed 2019-11-08 | $9.10M 10-Q · filed 2019-11-08 | $12.70M derived: sum of 4 quarters · filed 2020-02-21 | |
| 2018-06-30 | $2.80M 10-Q · filed 2019-08-08 | $5.60M 10-Q · filed 2019-08-08 | $9.20M derived: sum of 3 quarters · filed 2020-02-21 | $12.60M derived: sum of 4 quarters · filed 2020-02-21 | |
| 2018-03-31 | $2.80M 10-Q · filed 2019-05-02 | $6.40M derived: sum of 2 quarters · filed 2020-02-21 | $9.80M derived: sum of 3 quarters · filed 2020-02-21 | $13.50M derived: sum of 4 quarters · filed 2020-02-21 | |
| 2017-12-31 | $3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $7.00M derived: sum of 2 quarters · filed 2020-02-21 | $10.70M derived: sum of 3 quarters · filed 2020-02-21 | $13.80M 10-K · filed 2020-02-21 | |
| 2017-09-30 | $3.40M 10-Q · filed 2018-11-01 | $7.10M derived: sum of 2 quarters · filed 2018-11-01 | $10.20M 10-Q · filed 2018-11-01 | $13.40M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2017-06-30 | $3.70M 10-Q · filed 2018-08-02 | $6.80M 10-Q · filed 2018-08-02 | $10.00M derived: sum of 3 quarters · filed 2019-02-28 | $13.30M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2017-03-31 | $3.10M 10-Q · filed 2018-05-03 | $6.30M derived: sum of 2 quarters · filed 2019-02-28 | $9.60M derived: sum of 3 quarters · filed 2019-02-28 | $12.80M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2016-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $6.50M derived: sum of 2 quarters · filed 2019-02-28 | $9.70M derived: sum of 3 quarters · filed 2019-02-28 | $12.80M 10-K · filed 2019-02-28 | |
| 2016-09-30 | $3.30M 10-Q · filed 2017-11-08 | $6.50M derived: sum of 2 quarters · filed 2017-11-08 | $9.60M 10-Q · filed 2017-11-08 | $9.70M derived: sum of 4 quarters · filed 2018-02-28 | |
| 2016-06-30 | $3.20M 10-Q · filed 2017-08-02 | $6.30M 10-Q · filed 2017-08-02 | $6.40M derived: sum of 3 quarters · filed 2018-02-28 | $9.20M derived: sum of 4 quarters · filed 2018-02-28 | |
| 2016-03-31 | $100.00K 10-Q · filed 2017-05-04 | $3.10M 10-Q · filed 2016-05-02 | $3.20M derived: sum of 2 quarters · filed 2018-02-28 | $6.00M derived: sum of 3 quarters · filed 2018-02-28 | $8.70M derived: sum of 4 quarters · filed 2018-02-28 |
| 2015-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $5.90M derived: sum of 2 quarters · filed 2018-02-28 | $8.60M derived: sum of 3 quarters · filed 2018-02-28 | $11.20M 10-K · filed 2018-02-28 | |
| 2015-09-30 | $2.80M 10-Q · filed 2016-11-02 | $5.50M derived: sum of 2 quarters · filed 2016-11-02 | $8.10M 10-Q · filed 2016-11-02 | $17.50M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-06-30 | $2.70M 10-Q · filed 2016-08-04 | $5.40M 10-Q · filed 2016-08-04 | $14.70M derived: sum of 3 quarters · filed 2017-03-01 | $17.00M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-03-31 | $2.70M 10-Q · filed 2016-05-02 | $12.00M derived: sum of 2 quarters · filed 2017-03-01 | $14.30M derived: sum of 3 quarters · filed 2017-03-01 | $16.60M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2014-12-31 | $9.30M 10-K · filed 2017-03-01 | $11.60M derived: sum of 2 quarters · filed 2017-03-01 | $13.90M derived: sum of 3 quarters · filed 2017-03-01 | $9.30M 10-K · filed 2016-02-25 | |
| 2014-09-30 | $2.30M 10-Q · filed 2015-10-27 | $4.60M derived: sum of 2 quarters · filed 2015-10-27 | $6.70M 10-Q · filed 2015-10-27 | $7.90M derived: sum of 4 quarters · filed 2016-02-25 | |
| 2014-06-30 | $2.30M 10-Q · filed 2015-07-30 | $4.30M 10-Q · filed 2015-07-30 | $5.60M derived: sum of 3 quarters · filed 2016-02-25 | $6.40M derived: sum of 4 quarters · filed 2016-02-25 | |
| 2014-03-31 | $2.10M 10-Q · filed 2015-04-30 | $3.30M derived: sum of 2 quarters · filed 2016-02-25 | $4.10M derived: sum of 3 quarters · filed 2016-02-25 | $4.90M derived: sum of 4 quarters · filed 2016-02-25 | |
| 2013-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $2.00M derived: sum of 2 quarters · filed 2016-02-25 | $2.80M derived: sum of 3 quarters · filed 2016-02-25 | $3.70M 10-K · filed 2016-02-25 | |
| 2013-09-30 | $800.00K 10-Q · filed 2014-10-30 | $1.60M derived: sum of 2 quarters · filed 2014-10-30 | $2.50M 10-Q · filed 2014-10-30 | $3.40M derived: sum of 4 quarters · filed 2015-02-24 | |
| 2013-06-30 | $800.00K 10-Q · filed 2014-07-31 | $1.70M 10-Q · filed 2014-07-31 | $2.60M derived: sum of 3 quarters · filed 2015-02-24 | $3.50M derived: sum of 4 quarters · filed 2015-02-24 | |
| 2013-03-31 | $900.00K 10-Q · filed 2014-05-01 | $1.80M derived: sum of 2 quarters · filed 2015-02-24 | $2.70M derived: sum of 3 quarters · filed 2015-02-24 | $3.60M derived: sum of 4 quarters · filed 2015-02-24 | |
| 2012-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $1.80M derived: sum of 2 quarters · filed 2015-02-24 | $2.70M derived: sum of 3 quarters · filed 2015-02-24 | $3.60M 10-K · filed 2015-02-24 | |
| 2012-09-30 | $900.00K 10-Q · filed 2013-10-31 | $1.80M derived: sum of 2 quarters · filed 2013-10-31 | $2.70M 10-Q · filed 2013-10-31 | $3.40M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2012-06-30 | $900.00K 10-Q · filed 2013-08-06 | $1.80M 10-Q · filed 2013-08-06 | $2.50M derived: sum of 3 quarters · filed 2014-02-25 | $3.00M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2012-03-31 | $900.00K 10-Q · filed 2013-05-08 | $1.60M derived: sum of 2 quarters · filed 2014-02-25 | $2.10M derived: sum of 3 quarters · filed 2014-02-25 | $2.50M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2011-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $1.20M derived: sum of 2 quarters · filed 2014-02-25 | $1.60M derived: sum of 3 quarters · filed 2014-02-25 | $2.00M 10-K · filed 2014-02-25 | |
| 2011-09-30 | $500.00K 10-Q · filed 2012-11-01 | $900.00K derived: sum of 2 quarters · filed 2012-11-01 | $1.30M 10-Q · filed 2012-11-01 | ||
| 2011-06-30 | $400.00K 10-Q · filed 2012-08-09 | $900.00K 10-Q · filed 2012-08-09 | |||
| 2010-12-31 | $1.80M 10-K · filed 2013-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |